The headline on the online version of the article is slightly different: '3p pill cuts dementia risk by half'.
This story emerges from the launch, rather than the completion, of a four-year trial of losartan. The lead researcher, Dr Pat Kehoe, told Sense About Science:
"While we certainly have an attractive drug candidate both from the point of view of possible effect and the low cost, we cannot get ahead of ourselves here or over simplify things - we still have to conduct the study to generate the proper evidence before we can make any claims as to how useful the drug will be."
Posts
